Kornimate/medical-research-clean huggingface dataset:
auditory-motor coupling in multiple sclerosis with cerebellar lesions

Conditions: Multiple Sclerosis; Cerebral Lesion

Summary: this study is a case-control observational study, involving persons with multiple sclerosis and healthy controls. the study contains 1 descriptive and 4 experimental sessions. in the descriptive session, participant's clinical motor and cognitive functions are collected. in the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. in the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, at different tempi and alignment strategies. in the latter three sessions, apart from outcome measures of synchronization the following will be collected as well: spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.


Eligibility criteria:
inclusion criteria: * diagnosis of multiple sclerosis \>1 year, * type of lesions: cerebellar lesions, * walking speed 0.8-1.2m/s, ability to walk for 6 minutes continuously (canes and rollators are permitted). exclusion criteria: * relapse 3 months prior to enrollment, * cognitive impairment impeding understanding of instructions, * beat amusia, * deafness, * pregnancy
a socio-ecological approach for improving self-management in adolescents with scd

Conditions: Anemia, Sickle Cell

Summary: the goal of this clinical trial is to evaluate the impact of scthrive (a behavioral self-management intervention) on patient activation, self-management behaviors, daily functioning, and emergency room visits in 260 adolescents and young adults with sickle cell disease (scd) ages 13-21 receiving care at 1 of 4 pediatric scd clinics. the main question\[s\]it aims to answer are: * does scthrive improve patient activation? * does scthrive improve self-management behaviors, daily functioning, and decrease emergency room visits? * are any improvements maintained 3 months after treatment? participants will complete self-management related surveys before, after, and 3 months following their participation in an 8- week, virtual group intervention with an accompanying mobile app (scthrive). researchers will compare outcomes for participants who receive scthrive and participants who receive uniform standard care (schealthed which = standard of care plus scd educational text messages) to see if there are differences in patient activation, self-management behaviors, daily functioning, and emergency room visits.

the research team's pilot work demonstrated improved patient activation (knowledge, skills, and self-efficacy) and self-management behaviors in adolescents and young adults (aya) with sickle cell disease (scd) compared to a control condition. further analyses revealed that participants who used the app more frequently showed greater improvements. thus, this study will maximize the clinical benefit of scthrive by 1) adding app engagement strategies, 2) conducting a more systematic assessment of barriers including social contributors to health, and 3) integrating ways to address these barriers into the intervention. study aims: the aims are to examine the impact of scthrive on patient activation (primary outcome; aim 1) and self-management behaviors, daily functioning, and emergency room visits (secondary outcomes) at post-treatment and follow-up (aim 2). it is hypothesized that adolescents randomized to scthrive will have greater improvement in patient activation (primary outcome) compared to those randomized to uniform standard care (control condition). the research team will also explore the relationship between social determinants of health (sdoh)-related barriers (e.g., stigma, access to care) and treatment response (i.e., patient activation and self-management behaviors).

Eligibility criteria:
inclusion criteria: * patient of a participating scd clinic * confirmed diagnosis of scd * 13-21 years of age exclusion criteria: * another chronic disease (which would complicate measurement of patient activation) * non-english-speaking * cognitive or psychiatric disorder that the physician or study therapists believe would impair study participation.

Keywords: adolescent and young adult (aya) self-management behavioral intervention sickle cell disease
safety and efficacy of idh1r132h-dc vaccine in gliomas

Conditions: Glioma

Summary: this trial is aimed at evaluating the safety and efficacy of idh1r132h-dc vaccine in glioma with idh1r132h mutation.

eligible patients that provide written informed consent will undergo apheresis to collect blood mononuclear cells for vaccine production. all patients will receive mature dendritic cells for a total of 12 vaccine doses.the dc vaccine will be given subcutaneously every four weeks. peripheral blood will be taken two weeks after injection each time to monitor the immune response.

Eligibility criteria:
inclusion criteria: * the patient signed "informed consent" voluntarily; * the age of patient is between 18 and 70 years; * the tumor can be resected and tumor resection rate ≥80%; * idh1r132h mutation can be confirmed by immunohistochemistry or real-time quantitative pcr; * peripheral blood lymphocytes absolute value is not less than 0.8 × 106; * kps score ≥70 ; * the patient has normal bone marrow reserve and normal liver and kidney function ( the bone marrow, liver and kidney function must be confirmed by laboratory examination to meet the requirements of participating in the study within 3 days before the first acceptance of idh1r132h-dc tumor vaccine therapy): medium neutrophil absolute value ≥1,500 / mm3; hemoglobin\> 10g / dl; platelet count\> 100,000 / mm3; total bilirubin \<1.5 × uln; alanine aminotransferase / aspartate aminotransferase \<2.5 × uln; serum creatinine \<1.5 × uln; * normal heart function ; * better follow-up and compliance; * for women of childbearing age (15 to 49 years)，pregnancy test must be negative 7 days before starting this study. male and female patients of childbearing potential must agree to use effective contraceptive measures to ensure that during the study period and three months after cessation of treatment will not be pregnant. exclusion criteria: * the patient did not sign "informed consent" or signed unvoluntarily. * non-glioma patients * drugs for brain or antibody therapy had been used 4 weeks before the start of this study * active infection * human immunodeficiency virus (hiv) positive * hepatitis c or hepatitis b infective * pregnancy or breast-feeding women * patients did not agree to use effective contraception during treatment and the following 3 months. * patients also participated in other clinical studies. * the subjects researchers believe are not suitable for participation or completion of the study.

Keywords: idh1r132h dendritic cell glioma
gene methylation in the diagnosis of barrett's esophagus: identification of candidate diagnostic markers

Conditions: Barrett's Esophagus

Summary: this study is to identify potential markers from esophageal biopsies and brush cytology for feasibility of use in stool specimens for detection of barretts esophagus.


Eligibility criteria:
inclusion criteria: controls: no endoscopic evidence of barrett's esophagus, able to give informed consent, 18 years of age or older. cases: at least 1 cm of visible columnar epithelium with intestinal metaplasia on histology confirmed by an expert gi pathologist (on biopsy), able to give informed consent, 18 years of age or older. exclusion criteria: controls: patients with history of esophagectomy or mucosal ablation, gastrectomy, or known non-barrett's esophageal pathology (e.g. eosinophilic esophagitis or achalasia), varices, esophagitis la grade b, c, d will be excluded. patients with prior history of colon polyps or colon/esophageal/gastric/pancreatic carcinoma (unless had negative colonoscopy within 2 years to clear polyps). cases: patients with history of esophagectomy or mucosal ablation, gastrectomy, or known non-barrett's esophageal pathology (e.g. eosinophilic esophagitis or achalasia), will be excluded. patients with prior history of colon polyps or colon/gastric/pancreatic carcinoma (unless had negative colonoscopy within 2 years to clear polyps).

Keywords: barrett's esophagus
feasibility study on pori device

Conditions: Hand Spasticity

Summary: this study is a feasibility study of a new device that moves the hand of patients with spasticity to reduce hand muscle tone. the device's ability to improve spasticity before and after a 20-minute session with the device at yale new haven hospital's outpatient clinic of physical medicine \& rehabilitation, or the inpatient rehabilitation unit.

each patient will participate in a single 20 minute session, during which the device will extend and flex finger muscles. each participant's duration will be approximately 1 hour during clinic, including time to address any further questions, to calibrate the device, and to measure the modified ashworth score (mas) before and after the intervention.

Eligibility criteria:
inclusion criteria: * modified ashworth scale (mas) score of at least 1 * participants with paralysis or motor function problems of the fingers of one or both hands. exclusion criteria: * minors (below age 18) * vulnerable populations * inability of fingers and wrist to stretch to neutral during passive range of motion
self-perceived health status and healthcare consumption of idiopathic scoliosis patients treated more than 20 years ago: how much do operated and non-operated patients differ?

Conditions: Adolescent Idiopathic Scoliosis

Summary: adolescent idiopathic scoliosis (ais) is a common condition that affects millions of patients worldwide. this is characterized by a spinal deformity that leads to a deformation of the trunk, an imbalance of the shoulders and waist folds as well as the appearance of gibbosity. posterior arthrodesis correction is a common practice surgery for the treatment of ais after failure of medical treatment with a corset or functional rehabilitation. surgery allows functional improvement and is indicated for curves greater than medically treated scoliosis. the objective of this international study is to have a better understanding of the long-term outcomes (\> 20 years of follow-up) after treatment (surgical and non-surgical) of ais and to compare the long-term status of the patient with ais to the general population of the same age, sex and comorbidities. all of this information will help justify or modify the strategy, techniques and goals of early treatment in adolescence to achieve a better long-term outcome.


Eligibility criteria:
inclusion criteria: * diagnosis of adolescent idiopathic scoliosis * main baseline curve magnitude over 40º * aged 10 to 18 years at the time of treatment (surgical or nonsurgical) * more than 20 years of follow up * current contact information available exclusion criteria: * non-idiopathic scoliosis * younger than 10 or older than 18 at the time of initial treatment * less than 20 years of follow up * patients unable to understand and answer the questionnaires because of language difficulties or because of cognitive impairments
comparison of effectiveness of mobilization with movement (mwm) and kelternborn treatment technique to increase rom, reducing pain in patient of acl reconstruction

Conditions: Pain

Summary: to determine the comparison of effectiveness of mobilization with movement (mwm) and kelternborn treatment technique to increase rom, reducing pain in patient of acl reconstruction


Eligibility criteria:
inclusion criteria: * • subjects with age group between 20 to 60 years with sedentary lifestyle were included. * both males and females were included. * patients with diagnosed tight hamstrings having knee extension less than 160º with the hip at 90º flexion. * patients with decreased rom at the knee joint. * patients with reduced straight leg raise. * patients with pain in posterior compartment of thigh. * asymptomatic patients will be included. exclusion criteria: * • patients with prolapsed disc were excluded. * patients with lower extremity injuries (strain, sprain, ligament injuries, etc.) in last 6 months were excluded. * patients with severe hamstring injury either acute or chronic were excluded. * patients with visual acute swelling in the region of hamstring muscle * patients with fracture of any type and area. * patients with dislocations or subluxations present were excluded. * patient recommended for tkr of knee joint. * patients with any neurological disease like lumbar/cervical herniation, polyneuropathy, scoliosis etc.)
comparison of the effect of hydrophobic acrylic and silicone 3-piece iols on posterior capsule opacification

Conditions: Posterior Capsule Opacification; Cataract

Summary: age-related cataract is the main cause of impaired vision in the elderly population worldwide. the only treatment that can restore functional visual ability is cataract surgery where the opacified crystalline lens is removed by phacoemulsification and an artificial intraocular lens is implanted into the remaining capsular bag. cataract operations are generally very successful, with a low risk of serious complications. the most common reason for impaired vision after uneventful cataract surgery in otherwise healthy eyes is the development of posterior capsule opacification (pco). pco is a physiological change (thickening, opacification and clouding) of the capsular bag expected after cataract surgery, because the lens epithelial cells (lecs) undergo hyperplasia and cellular migration. pco is treated with nd:yag capsulotomy, a quick outpatient procedure that uses a laser to open a central hole in the posterior capsular bag. modifications in iol design and material lead to a decrease in the incidence of pco. during the past two decades, refinements in surgical technique were made resulting in today's small incision phacoemulsification surgery. nowadays a multitude of microincision iols are available, many of them similar but of course with some differences in regard to the chemical composition of the acrylic material and the iol design. the purpose of this study is to compare the development of posterior capsule opacification (pco) and the frequency of treatment between two different microincision iols over a period of 2 years.


Eligibility criteria:
inclusion criteria: * bilateral age-related cataract * good overall physical constitution exclusion criteria: * previous intraocular surgery or ocular trauma * intraocular complication like posterior capsular tear * glaucoma * uveitis * corneal diseases, diabetic retinopathy and any other severe retinal -pathology that would make a postoperative visual acuity of 20/40 (decimal equivalent = 0.5) or better unlikely
factors associated with in suboptimal prescribing for older patients with epilepsy

Conditions: Epilepsy

Summary: nearly 2% of veterans \>65 are actively treated for epilepsy, and the incidence is projected to increase with the aging of our society. since commonly used antiepileptic drugs are considered suboptimal for older patients, it is important to understand existing patterns of treatment for older veterans with epilepsy.

objective(s): 1. identify patient, provider, and system factors predicting adoption of recommended aeds for treatment of newly diagnosed older veterans (fy00-04). 2. identify barriers to use of recommended aed in initial therapy for newly diagnosed older veterans with epilepsy. 3. assess and compare effectiveness of long-term use of various aed. methods: using existing national va outpatient, inpatient, and pharmacy databases in conjunction with medicare inpatient and outpatient standard analytic files, the 1999 national health survey of va enrollees, american hospital association data, and primary data collection, we will identify the extent to which treatment for older veterans newly diagnosed with epilepsy changed between fy00-fy04, and identify predictors of change at the patient, provider, and system levels. we will begin to identify barriers to use of recommended aed using structured interviews with primary care and general neurology providers in sites with high and low use of suboptimal aeds in incident cases. finally, we will compare hospitalizations, emergency room visits, and fall-related injuries (including fractures) for patients on different aed regimens. results: we have identified 72,638 patients who are at least 66 years of age, have a diagnosis of epilepsy in va or medicare files, and who also received aeds from the va; 9,682 of of these are incident cases, 41,867 are chronic cases, and 21,089 have been defined as having unknown onset. we found wide variations in prescribing, an high rates of use of suboptimal aeds (70%). we identified sites with high and low use of suboptimal and new aeds. we have finalized provider interview protocols, and are in the process of gaining approval at individual sites. impact: the proposed study will enhance understanding of factors associated with adoption of clinical recommendations for newly diagnosed older patients with epilepsy, begin to identify barriers to their adoption, and assess outcomes of epilepsy patients on chronic aed therapy. this study will provide the foundation on which to develop interventions to improve care and will improve the quality of care for older veterans diagnosed with epilepsy.

Eligibility criteria:
inclusion criteria: veterans 66 years and older receiving care from the veterans health administration between fiscal years 2000-2004 diagnosis of epilepsy and receiving anticonvulsant drugs exclusion criteria: no va pharmacy data the year prior to epilepsy diagnosis

Keywords: epilepsy pharmacoepidemiology quality of care outcomes
spina bifida in daily life: an exploratory study

Conditions: Spina Bifida

Summary: spina bifida can lead to physical neurocognitive and psychological symptoms. still little is know about the daily impact of spina bifida on participation possibilities in social life. this exploratory research project want to investigate which lif choices patients with spina bifida has to make and in which way their daily life is organized. in a second part, quality of life will be measured and we hope to discover some dynamics in order to improve patient care.

this exploratory research project wants to investigate how patients with spina bifida live their daily life and which impact spina bifida has on their choices of life. this will be done by a survey that will ask questions about different domains in life: demographic variables, education, work, social functioning, spare time, housing, mobility, independency and quality of life. the survey is based on empirical findings in literature. the quality of life questioning is based on the sf36. the survey will be done once during a clinical consultation.

Eligibility criteria:
inclusion criteria: * patients diagnosed with spina bifida exclusion criteria: * not able to read or write dutch
bilateral dlpc tdcs in drug-resistant migraine

Conditions: Migraine

Summary: the goal of this clinical trial is to study and describe the effects of bilateral tdcs applied to dorso-lateral-prefrontal cortex (dlpc) in patients with drug-resistant migraine in terms of reduction in frequency of pain, impact of pain in daily life, quality of sleep and psychological measures. we finally planned to include high frequency and chronic migraine patients. the main questions it aims to answer are: * will bilateral dlpc tdcs be feasible, well tolerated and safe in drug resistant migraine patients? * will bilateral dlpc tdcs be effective in reducing pain frequency, intensity and its impact in daily life activities? * will bilateral dlpc tdcs be effective in ameliorating sleep and psychological associated symptoms? * will bilateral dlpc tdcs be such effective in reducing pain frequency, intensity and its impact in daily life activities as anti-cgrp treatments? participants will undergo 2 tdcs sessions daily for 2 consecutive weeks. patients will be blinded to treatment and will be divided in two groups (real vs placebo). a third group of patients, age-matched to the other two, will undergo anti-cgrp treatment. patients will be asked to complete patient-reported outcomes (proms) scales at baseline, one week after the end of the treatment and at 6 months after the end of the treatment. researchers (blinded to the treatment) will compare the group that underwent real tdcs treatment vs the one that underwent placebo tdcs vs the one that underwent anti-cgrp drugs to see if bilateral dlpc tdcs is effective in reducing migraine frequency, intensity and impact and if bilateral dlpc tdcs is such effective as anti-cgrp treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of high-frequency and/or chronic migraines, according to the diagnostic criteria of the ichd-iii, * failure to more than 3 preventive drugs * stable pharmacological treatment (\> 6 months without changes), * absence of other neurological or medical pathological conditions, * written informed consent. exclusion criteria: * seizures * significant cognitive impairment that prevents following orders and understanding instructions (mini-mental state examination \< 23) * pregnancy * aphasia or limitations in communication, * metallic cranial implants * another neurological or psychiatric pathology * diagnosis of another type of migraine.

Keywords: migraine drug-resistant tdcs dlpc neuromodulation anti cgrp
changing tactics? optimizing ect in difficult-to-treat depression

Conditions: Depression

Summary: the goal of this randomized controlled trial is to address which treatment strategy (continue right unilateral (rul) ect or switch to bitemporal (bt) ect speeds up recovery and has the least impact on memory function, in case of early non-response during an acute course of ect for difficult-to-treat depression. the main questions it aims to answer are: * assess the antidepressant efficacy and cognitive impact of the continuation of an ongoing treatment with rul ect compared to switching the treatment technique to bt ect, in patients failing to show an early response to an acute course of ect for major depression; * assess group and subject-specific trajectories of depressive symptom severity and neurocognitive performance during the acute ect course and up to 3 months post-treatment. participants treated with ect for depression, showing no 'response' (≥50 percent decrease in depressive symptom severity compared to baseline) after 4 treatment sessions, will be randomized to either switch to bt ect or continue with rul ect. mood and neurocognitive assessments will be performed at baseline, after 4 ect sessions (before randomization), after 8 ect sessions, at the end of the acute course and 3 month after the acute course.


Eligibility criteria:
inclusion criteria: * voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures * age 18 or older * diagnosis of major depressive disorder (dsm-5 296.21-30) or bipolar disorder, depressed (dsm-5 296.51-54; 296.84), confirmed by mini (mini international neuropsychiatric interview) exclusion criteria: * contra-indication for general anesthesia * non-dutch speaking * diagnosis of schizoaffective disorder or schizophrenia, confirmed by mini * diagnosis of substance use disorder in the past six months, confirmed by mini * diagnosis of neurocognitive disorder or intellectual disability alongside a moca score \<23 * previous ect course in the past three months * participation in an interventional trial with an investigational medicinal product or device * pregnancy

Keywords: electroconvulsive therapy depression cognition